Publications by authors named "Simon Waters"

Claim this Profile
C
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Maria Coakley, Guillermo Villacampa, Prithika Sritharan, Claire Swift, Kathryn Dunne, Simon Waters

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial.
Mark Beresford, Angela Casbard, Zoe Hudson, Margherita Carucci, Kate Ingarfield, Simon Waters

BJC Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Ailsa J Oswald, Stefan N Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Simon Waters

Breast Cancer Res Treat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Amit Bahl, William Wilson, Jessica Ball, Emily Renninson, Sidharth Dubey, Simon Waters

Breast· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, Guillermo Streich, Alberto J Montero, Simon Waters

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.
Hans Wildiers, Thomas Meyskens, Sandrine Marréaud, Lissandra Dal Lago, Peter Vuylsteke, Simon Waters

Breast· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Sacha J Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Simon Waters

Lancet Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M Brufksy, Simon H Waters

Clin Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Robert H Jones, Angela Casbard, Margherita Carucci, Catrin Cox, Rachel Butler, Simon Waters

Lancet Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Nicolò Matteo Luca Battisti, Belinda Kingston, Judy King, Arshi Denton, Simon Waters

Breast Cancer Res Treat· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters

Lancet Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.
Tomoyuki Tanaka, Helen Sewell, Simon Waters, Simon E V Phillips, Terence H Rabbitts

J Biol Chem· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The AusPSIs: the Australian version of the Agency of Healthcare Research and Quality patient safety indicators.
Steven McConchie, Jennie Shepheard, Simon Waters, Alison J McMillan, Vijaya Sundararajan

Aust Health Rev· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis